Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Palisade Bio, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 13 | 11 | −2 |
| Shares | 296.4K | 84.6K | −211.7K (−71.5%) |
| Value | $200.9K | $57.5K | −$143.4K (−71.4%) |
New holders (3)
Institutions that held Palisade Bio, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 27,337 | $18.6K | 0.00% |
| Newbridge Financial Services Group, Inc. | 10,500 | $7.14K | 0.00% |
| Transce3nd, LLC | 1,000 | $680 | 0.00% |
Sold out (5)
Institutions that held Palisade Bio, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Armistice Capital, LLC | 144,764 | $98.6K |
| Marex Group plc | 35,759 | $24.3K |
| HRT Financial LP | 18,264 | $12.0K |
| Virtu Financial LLC | 15,255 | $10.0K |
| Barclays PLC | 6 | $4 |